HB-500 is a next-generation therapeutic vaccine being developed in collaboration with Gilead Sciences, Inc. (Gilead) as a potential component of a curative regimen for human immunodeficiency virus (HI ...

Cognizant (NASDAQ: CTSH) has announced an expansion of its longstanding relationship with biopharmaceutical leader Gilead Sciences (NASDAQ: GILD) that aims to unlock even greater value for Gilead as ...

HB-500 is a next-generation therapeutic vaccine being developed in collaboration with Gilead Sciences, Inc. (Gilead) as a potential component of ...

Driven by rapid innovations and the integration of modern technologies, the biotech sector is experiencing robust growth.

Gilead Sciences, Inc. (NASDAQ:GILD), a leading biopharmaceutical company with a market capitalization of $119.32 billion, has been making significant strides in its core HIV franchise while expanding ...

Gilead Sciences Inc. closed 3.35% below its 52-week high of $98.90, which the company achieved on November 11th.

In the assessment of 12-month price targets, analysts unveil insights for Gilead Sciences, presenting an average target of ...

Tyler Van Buren, an analyst from TD Cowen, maintained the Buy rating on Gilead Sciences (GILD – Research Report). The associated price target ...

J.P. Morgan analyst Chris Schott maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of $115.00.

In the most recent trading session, Gilead Sciences (GILD) closed at $93.85, indicating a -1.57% shift from the previous trading day.

Reported a robust objective response rate of 75.5% from the Phase 1 study of NX-5948 in patients with relapsed/refractory CLL/SLL at the 66th ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2024 financial results and 2025 ...